Architecting agility: How Incyte is shaping the global market for scientific talent

In this interview, Soni Basi, Ph.D., EVP and CHRO at Incyte, shares how this global biopharmaceutical leader is putting the focus on predictive talent strategies. By blending social psychology with AI-driven agility, Incyte creates a culture where elite scientific minds truly thrive. Cielo is supporting Incyte on this journey, collaborating to navigate the complex global market and secure the talent that powers life-saving innovation.

How can HR move from reacting to the market to actively shaping it?

In the fast-paced world of life sciences, "business as usual" is a relic of the past. As we expand our global footprint and grow our position as a major force in the biopharmaceutical landscape, the challenges are mounting.

We’re dealing with changing government regulations, complex global payer systems, and a hyper-competitive market for top-tier scientific talent. Our mission extends beyond filling seats; we are committed to ensuring that the scientists discovering life-saving medicines have the support they need to reach patients around the world.

One of the things keeping me up at night is the global landscape of pharma. Many HR functions operate in a reactive loop: a role opens, and recruiters scramble to fill it. I’m leading a transition at Incyte toward a predictive model where our talent function anticipates market changes before they happen.

To me, agility is more than an industry trend; it’s a survival mechanism. We focus on identifying where the 'center for scientific talent' is moving globally, tracking shifts from traditional locations to emerging markets half a world away. By mapping these trends, Incyte proactively attracts and develops talent on a global scale, ensuring we shape the market rather than merely reacting to local shortages.

What is your approach to maintaining an authentic culture and how are you integrating AI into your talent strategy?

My approach is deeply rooted in my academic background in social psychology. I view the organization as a living ecosystem where culture and business strategy must be perfectly aligned to drive performance.

Culture requires a deep understanding of human behavior and motivation. I’m moving us toward a model where leadership sets the tone, but employees are empowered to adopt it authentically. We achieve this through leader-led transparency; by sharing the challenges and uncertainties faced by top executives, we foster a culture of psychological safety.

I’m also a proponent of using AI and analytics, but I view technology as a force multiplier for human judgment. AI should serve the recruiter, not replace the human element. We are preparing our workforce for a "digital-first" future where AI handles the routine, leaving our people to focus on high-value scientific innovation.

You’ve talked about the need for organizational resilience. How do you actually cultivate that within your teams?

To me, resilience comes from a talent-first philosophy. In a market where scientific expertise is incredibly scarce, I always say that people build careers by making "courageous moves."

I prioritize building talent from within rather than relying solely on external hiring. That’s why we’re creating clear pathways for internal mobility, ensuring that no one is reliant on holding one specific position for their entire tenure. This fluidity doesn’t just increase retention — it makes us more resilient to sudden market fluctuations and keeps our "heart and soul" (our R&D talent) engaged and growing.

Life sciences is a uniquely high-stakes and highly regulated space. How does that reality shape your talent strategy?

We operate in an ecosystem where access to medicines and pricing transparency are under constant scrutiny. We view these regulatory complexities as a vital part of our mission, rather than just a hurdle to clear. Our R&D talent is discovering novel, life-saving medicines that patients around the world depend on. Because of that, my strategy involves equipping our workforce to handle intense external pressures, from market access readiness to navigating complex global payer systems, without losing sight of the ultimate goal—serving patients.

What advice can you offer CHROs as they prepare for the future?

The future of HR is about becoming a strategic business architect. To get there, we’re focusing on three specific pillars that I think are essential for any forward-looking organization.

First, there’s data fluency. Data is the language of the C-suite now, and we have to bring that same scientific rigor and long-term outlook to our talent strategy that our researchers bring to their work in the lab. It’s about moving past “gut feel” and treating talent as a measurable, predictable asset.

I view culture as more than a static set of values; it is an active ecosystem built through leader-led transparency. When our top executives are open about their own challenges and uncertainties, it creates the psychological safety our people need to stay agile and keep innovating.

Finally, everything rests on a talent-first philosophy. We’re shifting from a buying mindset to a building one — creating real pathways for internal mobility. When we encourage our employees to make those courageous moves into new roles, we’re ensuring the whole organization is resilient enough to handle whatever market fluctuations come our way.

How has your partnership with Cielo enabled you to execute this kind of predictive, architectural strategy?

Building this architecture requires the right support. In a high-growth environment, we can't afford to be bogged down by administrative hurdles. Cielo acts as an extension of our team, providing the global infrastructure and market insights that allow my internal leaders to focus on the work that matters most. By leveraging their expertise, we’ve moved away from a reactive, vacancy-filling mindset and gained the breathing room to look 10 years ahead — anticipating where the next center of scientific excellence will be.